{"id":"pancreatic-enzyme","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain or cramping"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hyperuricemia (with high-dose use)"}]},"_chembl":{"chemblId":"CHEMBL4456859","moleculeType":"Unknown","molecularWeight":"4050.58"},"_dailymed":{"setId":"59ddb2e4-058e-4b11-a0ef-3cb1845d3051","title":"PANCREATIC ENZYME CONCENTRATE TABLET [COVETRUS NORTH AMERICA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pancreatic enzyme replacement therapy (PERT) provides exogenous pancreatic enzymes to compensate for pancreatic insufficiency, enabling proper digestion of fats, proteins, and carbohydrates in the small intestine. This restores nutrient absorption and reduces malabsorption symptoms in patients with chronic pancreatitis, cystic fibrosis, pancreatic cancer, or post-surgical pancreatic dysfunction.","oneSentence":"Pancreatic enzymes replace or supplement the natural digestive enzymes (amylase, lipase, protease) that the pancreas fails to produce adequately.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:43:52.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic insufficiency secondary to chronic pancreatitis"},{"name":"Cystic fibrosis-related pancreatic insufficiency"},{"name":"Post-pancreatic surgery pancreatic insufficiency"},{"name":"Pancreatic cancer-related malabsorption"}]},"trialDetails":[{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT05788744","phase":"NA","title":"Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer","status":"RECRUITING","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2023-01-01","conditions":"Resectable Pancreatic Cancer","enrollment":1000},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT07490301","phase":"PHASE2, PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, PDAC","enrollment":900},{"nctId":"NCT07488299","phase":"NA","title":"The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2026-03-20","conditions":"Pancreatic Walled-off Necrosis","enrollment":120},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":176},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT05659147","phase":"PHASE4","title":"Imaging Biomarkers of Pancreatic Function and Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-01-18","conditions":"Pancreatitis, Diabetes Mellitus","enrollment":195},{"nctId":"NCT07479238","phase":"","title":"Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-03-15","conditions":"SIBO, Pancreatic Insufficiency, Chronic Pancreatitis","enrollment":100},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":123},{"nctId":"NCT07450547","phase":"PHASE2","title":"Phase 2 Study to Assess the Safety and Efficacy of ANG003","status":"NOT_YET_RECRUITING","sponsor":"Anagram Therapeutics, Inc.","startDate":"2026-04","conditions":"Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)","enrollment":113},{"nctId":"NCT07441824","phase":"PHASE3","title":"Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-02","conditions":"Acute Necrotizing Pancreatitis, Pancreatic Exocrine Insufficiency","enrollment":140},{"nctId":"NCT06949735","phase":"PHASE2","title":"Clinical Trial on Digestive Enzymes: Effects on Post-Meal Response to High-Macronutrient Meals","status":"COMPLETED","sponsor":"Pancap Pharma Inc.","startDate":"2025-07-11","conditions":"Gastrointestinal Digestion, Healthy, Gastrointestinal Wellbeing","enrollment":24},{"nctId":"NCT05642962","phase":"PHASE1, PHASE2","title":"Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-30","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":17},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT05279079","phase":"","title":"Markers in Acute Pancreatitis-1","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2023-01-25","conditions":"Acute Pancreatitis Drug-Induced","enrollment":175},{"nctId":"NCT07418593","phase":"PHASE4","title":"THE MALABSORPTION BLOOD TEST TRIAL WILL HELP DETERMINE THE BENEFITS OF PANCREATIC ENZYME REPLACEMENT THERAPY IN PATIENTS WITH MILD TO MODERATE EXOCRINE PANCREATIC INSUFFICIENCY.","status":"RECRUITING","sponsor":"Anna Evans Phillips","startDate":"2026-03","conditions":"Chronic Pancreatitis, Recurrent Acute Pancreatitis, Exocrine Pancreatic Insufficiency","enrollment":80},{"nctId":"NCT05466799","phase":"PHASE2","title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoSil Medical Limited","startDate":"2023-04-26","conditions":"Locally Advanced Pancreatic Cancer","enrollment":88},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT06219941","phase":"PHASE2","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer","enrollment":224},{"nctId":"NCT04340141","phase":"PHASE3","title":"Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2020-10-13","conditions":"Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer","enrollment":358},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07214298","phase":"PHASE1, PHASE2","title":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-01","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":35},{"nctId":"NCT02784990","phase":"","title":"Study of Pancreatic Enzymes in the Drains as Early Biomarkers of Post-operative Pancreatic Fistula and Its Clinical Repercussions","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2016-06-03","conditions":"Pancreatic Fistula","enrollment":770},{"nctId":"NCT07236177","phase":"EARLY_PHASE1","title":"B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2026-02-03","conditions":"Breast Cancer, Pancreatic Cancer, Pulmonary Cancer","enrollment":220},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT06381154","phase":"PHASE2","title":"Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-12-06","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":25},{"nctId":"NCT04421820","phase":"PHASE1, PHASE2","title":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","status":"RECRUITING","sponsor":"Bold Therapeutics, Inc.","startDate":"2020-08-28","conditions":"Colorectal Cancer, Pancreatic Cancer, Gastric Cancers","enrollment":220},{"nctId":"NCT04098237","phase":"PHASE2","title":"Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew Hendifar, MD","startDate":"2020-12-17","conditions":"Pancreatic Adenocarcinoma","enrollment":36},{"nctId":"NCT06058442","phase":"PHASE3","title":"The Pancreatic Enzymes After Gastrectomy Trial","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2024-01-24","conditions":"Gastrectomy","enrollment":188},{"nctId":"NCT05026905","phase":"PHASE2","title":"A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-12-28","conditions":"Phase II, Open-label, Parallel 2-arm, Multi-center","enrollment":66},{"nctId":"NCT05688215","phase":"PHASE1, PHASE2","title":"Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2023-03-07","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma","enrollment":56},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07335523","phase":"PHASE2","title":"Management of Steatorrhea in Children and Young Adults With Alagille Syndrome After Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Digestive Care, Inc.","startDate":"2026-03","conditions":"Steatorrhea","enrollment":30},{"nctId":"NCT03977233","phase":"PHASE2","title":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT07325214","phase":"NA","title":"Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"IMGT Co., Ltd.","startDate":"2026-04","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer","enrollment":136},{"nctId":"NCT03322995","phase":"PHASE2","title":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2018-06-21","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT06821997","phase":"PHASE2","title":"NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-02-01","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT07314489","phase":"EARLY_PHASE1","title":"A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2025-04-01","conditions":"Chronic Pancreatitis Pancreatic Exocrine Insufficiency Blood Glucose","enrollment":80},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT04752696","phase":"PHASE2","title":"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2021-05-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":"Pancreatic Cancer","enrollment":328},{"nctId":"NCT06385925","phase":"PHASE1, PHASE2","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","startDate":"2024-04-29","conditions":"Malignant Neoplasm","enrollment":440},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT07238283","phase":"PHASE3","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-02","conditions":"First-line Treatment of Metastatic Pancreatic Cancer","enrollment":662},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06941857","phase":"PHASE2","title":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-04","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT05034627","phase":"PHASE1","title":"Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-08-09","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":15},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT05417386","phase":"PHASE1","title":"FOLFIRINOX + NIS793 in Pancreatic Cancer","status":"TERMINATED","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-08-09","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":4},{"nctId":"NCT07076212","phase":"PHASE2","title":"Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-07","conditions":"Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":52},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT05482893","phase":"PHASE1, PHASE2","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2023-03-15","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)","enrollment":258},{"nctId":"NCT06477159","phase":"PHASE4","title":"Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-02-01","conditions":"Exocrine Pancreatic Insufficiency","enrollment":60},{"nctId":"NCT06544655","phase":"PHASE1","title":"A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-10","conditions":"Advanced Solid Tumors","enrollment":213},{"nctId":"NCT06576037","phase":"PHASE1","title":"Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-31","conditions":"Solid Tumor","enrollment":128},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT03184870","phase":"PHASE1, PHASE2","title":"A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-08-08","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":332},{"nctId":"NCT07211568","phase":"PHASE3","title":"PERT in Acute Necrotizing Pancreatitis","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-10-01","conditions":"Acute Pancreatitis Necrotizing, Nutrition Assessment","enrollment":188},{"nctId":"NCT01154608","phase":"NA","title":"Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis","status":"COMPLETED","sponsor":"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement","startDate":"2005-04","conditions":"Pancreatitis","enrollment":11},{"nctId":"NCT01494909","phase":"NA","title":"Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2010-11-15","conditions":"Cystic Fibrosis","enrollment":30},{"nctId":"NCT06826105","phase":"NA","title":"Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO)","status":"RECRUITING","sponsor":"Philipp Schuetz","startDate":"2025-09-22","conditions":"Malnutrition","enrollment":20},{"nctId":"NCT07096362","phase":"PHASE2","title":"Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-09-09","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":50},{"nctId":"NCT04919226","phase":"PHASE3","title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":259},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT06756503","phase":"","title":"Exocrine Pancreatic Insufficiency and Functional Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Maria Marta Piskorz","startDate":"2025-09-01","conditions":"Exocrine Pancreatic Insufficiency, Dyspepsia","enrollment":65},{"nctId":"NCT04141995","phase":"PHASE2","title":"FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2021-02-12","conditions":"Pancreas Cancer, Adenocarcinoma of the Pancreas","enrollment":11},{"nctId":"NCT06757348","phase":"","title":"Fatty Liver and Pancreatic Steatosis","status":"NOT_YET_RECRUITING","sponsor":"Maria Marta Piskorz","startDate":"2025-09-01","conditions":"Exocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic, Pancreatic Steatosis","enrollment":61},{"nctId":"NCT07074379","phase":"NA","title":"Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-21","conditions":"Painless Chronic Pancreatitis","enrollment":126},{"nctId":"NCT04348045","phase":"PHASE2","title":"Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2020-12-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":307},{"nctId":"NCT03806309","phase":"PHASE2","title":"OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2021-04-10","conditions":"Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer","enrollment":106},{"nctId":"NCT06149546","phase":"NA","title":"Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)","status":"RECRUITING","sponsor":"Cancer Trials Ireland","startDate":"2024-05-01","conditions":"Pancreatic Cancer","enrollment":70},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT04292743","phase":"PHASE1","title":"Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2020-12-02","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":19},{"nctId":"NCT06099119","phase":"PHASE4","title":"Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.","status":"RECRUITING","sponsor":"Hospital Clinico Universitario de Santiago","startDate":"2024-02-20","conditions":"Unresectable Pancreatic Cancer","enrollment":100},{"nctId":"NCT06897644","phase":"PHASE3","title":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-03-27","conditions":"Pancreatic Adenocarcinoma Advanced or Metastatic","enrollment":340},{"nctId":"NCT06691919","phase":"NA","title":"Surgical vs Endoscopic Resection of Walled Off Pancreatic Necrosis Using the Powered Endoscopic Debridement System","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-03","conditions":"Pancreatic Necrosis, Pancreatitis","enrollment":62},{"nctId":"NCT04965311","phase":"PHASE2","title":"Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-03-01","conditions":"Pancreatic Carcinoma","enrollment":4},{"nctId":"NCT06962254","phase":"PHASE1","title":"Imatinib and Trametinib for KRAS-mutated Solid Tumor","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2025-05-10","conditions":"Solid Tumor Cancer","enrollment":10},{"nctId":"NCT02896907","phase":"EARLY_PHASE1","title":"Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2016-10-18","conditions":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":8},{"nctId":"NCT05383352","phase":"PHASE1","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-05-30","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":177},{"nctId":"NCT06483555","phase":"PHASE1, PHASE2","title":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-02-06","conditions":"Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm","enrollment":104},{"nctId":"NCT06925204","phase":"","title":"Natural Course and Therapeutic Effect of Chronic Pancreatitis","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-04-13","conditions":"Chronic Pancreatitis","enrollment":5000},{"nctId":"NCT06581653","phase":"NA","title":"Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-08-15","conditions":"Chronic Pancreatitis, Pancreatic Exocrine Insufficiency","enrollment":204},{"nctId":"NCT06915129","phase":"NA","title":"The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals","status":"COMPLETED","sponsor":"Oregon State University","startDate":"2021-10-25","conditions":"Modulation of the Human Gut Microbiota by Prebiotic Galactooligosaccharides (GOS)","enrollment":12},{"nctId":"NCT05266963","phase":"EARLY_PHASE1","title":"Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-09-02","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT05494866","phase":"PHASE1","title":"A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"German Cancer Research Center","startDate":"2022-12-07","conditions":"CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer","enrollment":6},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT06813079","phase":"PHASE2","title":"Using Tumor Models to Determine Treatments","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-02-17","conditions":"Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor","enrollment":25},{"nctId":"NCT03822936","phase":"PHASE2","title":"Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma","status":"TERMINATED","sponsor":"CNAO National Center of Oncological Hadrontherapy","startDate":"2018-02-08","conditions":"Cancer of Pancreas, Pancreas Adenocarcinoma, Resectable Pancreatic Cancer","enrollment":30},{"nctId":"NCT05472259","phase":"PHASE2","title":"A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)","status":"RECRUITING","sponsor":"Belgian Group of Digestive Oncology","startDate":"2022-05-25","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3014,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CREON","Creon"],"phase":"marketed","status":"active","brandName":"Pancreatic Enzyme","genericName":"Pancreatic Enzyme","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pancreatic enzymes replace or supplement the natural digestive enzymes (amylase, lipase, protease) that the pancreas fails to produce adequately. Used for Pancreatic exocrine insufficiency secondary to chronic pancreatitis, Pancreatic exocrine insufficiency in cystic fibrosis, Pancreatic exocrine insufficiency following pancreatic surgery or pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}